Quick Takeaways: Why It Matters? ECO’s licence of Vaxinano’s late‑stage sheep toxoplasmosis vaccine gives it a low‑cost, de‑risked way to add a high‑value preventative product that directly tackles a major cause of abortion and lamb losses, with peak sales estimated a...
Quick Takeaways: Why It Matters? Boehringer Ingelheim’s purchase of Evax gives it a promising new way to treat common horse allergies with longer‑lasting vaccines instead of short‑term symptom relief, which could mean fewer vet visits and better outcomes for owners. If the approach works a...
Quick Takeaways: Why It Matters? The deal strengthens Magapor’s ability to expand beyond its 60+ country footprint by adding growth capital for R&D, commercial expansion and product development in a niche but defensible livestock-reproduction category, while allowing the Mena Gericó fa...
Quick Takeaways: Why It Matters? Elanco Ventures adds a structured, early-stage venture arm to Elanco’s strategy, giving the company a dedicated channel to access and co-develop emerging animal health technologies before they become mature competitors or acquisition targets. The ...
Quick Takeaways: Why It Matters? Viyash is using BioForLife as a front-end platform to scale its companion animal business in Europe, starting with Italy, one of the continent’s largest and fastest-growing pet health markets. Market-wise, the all-cash ...
